mRNA, Protein Vaccine Compositions for Influenza
Summary
The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.
What changed
The USPTO published patent application US20260097112A1 disclosing vaccine compositions containing multiple distinct influenza antigens. The compositions can be formulated as mRNA/LNP, recombinant protein, virus-like particles, or DNA vaccines. The application claims methods for preventing influenza infection and inducing immune responses.
For pharmaceutical and biotechnology companies developing influenza vaccines, this published application establishes prior art and signals potential competitive IP landscape considerations. Companies should review the claimed antigen combinations and delivery formulations for freedom-to-operate implications in their own vaccine development programs.
What to do next
- Monitor patent database for prosecution updates
- Review claims for freedom-to-operate analysis
- Assess IP portfolio implications for vaccine development programs
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
VACCINE COMPOSITIONS AND USES THEREOF
Application US20260097112A1 Kind: A1 Apr 09, 2026
Inventors
Jacob Glanville, Rishi Bedi, Nicholas Bayless, Sangil Kim, Gusti Zeiner, Sawsan Youssef
Abstract
The present disclosure provides vaccine compositions comprising a plurality of distinct antigens. Also provided are nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens. The plurality of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mRNA/LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of inducing an immune response are also disclosed.
CPC Classifications
A61K 39/145 A61P 37/04 C07K 14/005 A61K 2039/53 A61K 2039/6093 C12N 2760/16022 C12N 2760/16034 C12N 2760/16071
Filing Date
2025-10-17
Application No.
19361440
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.